Yael Naaman , Deborah Neesham , Antonia Jones , Rosemary McBain , Tom Cade , Orla McNally
{"title":"结合腹腔镜间隔期细胞减少手术治疗晚期卵巢癌","authors":"Yael Naaman , Deborah Neesham , Antonia Jones , Rosemary McBain , Tom Cade , Orla McNally","doi":"10.1016/j.cson.2023.100028","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To assess the utility of laparoscopy for interval cytoreductive surgery (CRS) in patients with advanced ovarian cancer after Neo-Adjuvant Chemotherapy (NACT).</p></div><div><h3>Methods</h3><p>A retrospective cohort study of interval CRS by laparoscopy in patients with advanced epithelial ovarian cancer treated at a single tertiary gynaecological cancer centre between October 2017 and September 2020.</p></div><div><h3>Results</h3><p>86 patients had interval CRS by the laparoscopic route during the study period. The optimal cytoreduction rate (R < 1 cm) was 92%, and complete cytoreduction rate with no residual disease (R = 0) was 35%. The intra-operative complication rate was 8% and the estimated blood loss (EBL) was 90 ml. The post-operative complication rate was 15%, mostly grade I-II, and the median length of hospital stay was 3 days.</p></div><div><h3>Conclusion</h3><p>For most patients with advanced ovarian cancer after NACT, laparoscopic interval CRS is feasible and effective in achieving optimal cytoreduction while providing a favourable peri-operative outcome. In some cases, however, recourse to laparotomy will optimise complete macroscopic resection.</p></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"2 4","pages":"Article 100028"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773160X2300020X/pdfft?md5=e679af68b402c7131a0392b47f71f5a0&pid=1-s2.0-S2773160X2300020X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Incorporating laparoscopic interval cytoreductive surgery for advanced ovarian cancer-lessons learnt\",\"authors\":\"Yael Naaman , Deborah Neesham , Antonia Jones , Rosemary McBain , Tom Cade , Orla McNally\",\"doi\":\"10.1016/j.cson.2023.100028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To assess the utility of laparoscopy for interval cytoreductive surgery (CRS) in patients with advanced ovarian cancer after Neo-Adjuvant Chemotherapy (NACT).</p></div><div><h3>Methods</h3><p>A retrospective cohort study of interval CRS by laparoscopy in patients with advanced epithelial ovarian cancer treated at a single tertiary gynaecological cancer centre between October 2017 and September 2020.</p></div><div><h3>Results</h3><p>86 patients had interval CRS by the laparoscopic route during the study period. The optimal cytoreduction rate (R < 1 cm) was 92%, and complete cytoreduction rate with no residual disease (R = 0) was 35%. The intra-operative complication rate was 8% and the estimated blood loss (EBL) was 90 ml. The post-operative complication rate was 15%, mostly grade I-II, and the median length of hospital stay was 3 days.</p></div><div><h3>Conclusion</h3><p>For most patients with advanced ovarian cancer after NACT, laparoscopic interval CRS is feasible and effective in achieving optimal cytoreduction while providing a favourable peri-operative outcome. In some cases, however, recourse to laparotomy will optimise complete macroscopic resection.</p></div>\",\"PeriodicalId\":100278,\"journal\":{\"name\":\"Clinical Surgical Oncology\",\"volume\":\"2 4\",\"pages\":\"Article 100028\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2773160X2300020X/pdfft?md5=e679af68b402c7131a0392b47f71f5a0&pid=1-s2.0-S2773160X2300020X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Surgical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2773160X2300020X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Surgical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2773160X2300020X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Incorporating laparoscopic interval cytoreductive surgery for advanced ovarian cancer-lessons learnt
Objective
To assess the utility of laparoscopy for interval cytoreductive surgery (CRS) in patients with advanced ovarian cancer after Neo-Adjuvant Chemotherapy (NACT).
Methods
A retrospective cohort study of interval CRS by laparoscopy in patients with advanced epithelial ovarian cancer treated at a single tertiary gynaecological cancer centre between October 2017 and September 2020.
Results
86 patients had interval CRS by the laparoscopic route during the study period. The optimal cytoreduction rate (R < 1 cm) was 92%, and complete cytoreduction rate with no residual disease (R = 0) was 35%. The intra-operative complication rate was 8% and the estimated blood loss (EBL) was 90 ml. The post-operative complication rate was 15%, mostly grade I-II, and the median length of hospital stay was 3 days.
Conclusion
For most patients with advanced ovarian cancer after NACT, laparoscopic interval CRS is feasible and effective in achieving optimal cytoreduction while providing a favourable peri-operative outcome. In some cases, however, recourse to laparotomy will optimise complete macroscopic resection.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
